Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TAK-442 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| TAK-442 10 mg BID | EXPERIMENTAL | Added with standard care for recurrent ischemic events. |
| TAK-442 20 mg BID | EXPERIMENTAL | Added with standard care for recurrent ischemic events |
| TAK-442 40 mg QD | EXPERIMENTAL | Added with standard care for recurrent ischemic events |
| TAK-442 40 mg BID | EXPERIMENTAL | Added with standard care for recurrent ischemic events |
| TAK-442 80 mg QD | EXPERIMENTAL | Added with standard care for recurrent ischemic events |
| TAK-442 80 mg BID | EXPERIMENTAL | Added with standard care for recurrent ischemic events |
| TAK-442 160 mg QD | EXPERIMENTAL | Added with standard care for recurrent ischemic events |
| TAK-442 120 mg BID | EXPERIMENTAL | Added with standard care for recurrent ischemic events |
| Placebo | PLACEBO_COMPARATOR | Added with standard care for recurrent ischemic events |
| Enoxaparin 30 mg BID | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| TAK-442 | DRUG | Stage I: TAK-442 10 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks. |
| Placebo | DRUG | Stages I, II \& III: TAK-442 placebo-matching capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks. |
| Enoxaparin | DRUG | Enoxaparin 30 mg, syringe, subcutaneous injection, twice daily for up to 10 days. |
Inclusion Criteria: * Has been hospitalized for acute coronary syndrome * Is able to initiate study drug if: * The index event occurred within the past 7 days (the date of initial hospitalization will be utilized for the date on which the index event occurred), and * The final acute medical or...
TAK-442 is an investigational small molecule being studied for the treatment of Acute Coronary Syndrome and Venous Thromboembolism. It is in Phase 2 clinical development and is not approved by the FDA. TAK-442 is being developed by Takeda Pharmaceutical Company Limited.
TAK-442 is a small molecule that targets factor Xa, a key enzyme in the coagulation cascade. By inhibiting factor Xa, TAK-442 is designed to reduce blood clot formation, which is relevant to its potential use in Acute Coronary Syndrome and Venous Thromboembolism.
TAK-442 is being developed by Takeda Pharmaceutical Company Limited, a global biopharmaceutical company. Takeda is conducting clinical trials to evaluate the safety and efficacy of TAK-442 in patients with cardiovascular conditions.
TAK-442 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. Two Phase 2 trials have been completed, one in Venous Thromboembolism and one in Acute Coronary Syndrome.
TAK-442 has been studied in two completed Phase 2 trials. NCT00641732 evaluated TAK-442 in patients undergoing total knee replacement for Venous Thromboembolism, enrolling 1,045 participants. NCT00677053 evaluated TAK-442 in patients with Acute Coronary Syndromes, enrolling 2,753 participants.
TAK-442 is also known by its chemical name, and it is a direct factor Xa inhibitor. It is not the same as other marketed anticoagulants, as it is a distinct investigational compound developed by Takeda. No alternative brand names have been established.